melanoma

     

Select            
Trial Studied trt Control trt patientstagsROB Trial result

B-Raf enzyme inhibitors

encorafenib plus binimetinib
COLUMBUS, 2018      NCTencorafenib plus binimetinibvemurafenib1LRisk of bias -
trametinib + dabrafenib
Flaherty, 2012      NCTtrametinib and dabrafenibdabrafenib -
COMBI-D (Long), 2014        NCTtrametinib and dabrafenibdabrafenib1L unresectable -
COMBI-AD, 2017      NCTtrametinib and dabrafenibplaceboadjuvantLow risk of bias -
COMBI-V (Robert), 2015      NCTtrametinib and dabrafenibvemurafenib1L -
vemurafenib and cobimetinib
Larkin, 2014      NCTvemurafenib and cobimetinibvemurafenib -

combined BRAF-MEK inhibitors

encorafenib plus binimetinib
COLUMBUS, 2018      NCTencorafenib plus binimetinibvemurafenib1LRisk of bias -
trametinib + dabrafenib
Flaherty, 2012      NCTtrametinib and dabrafenibdabrafenib -
COMBI-D (Long), 2014        NCTtrametinib and dabrafenibdabrafenib1L unresectable -
COMBI-AD, 2017      NCTtrametinib and dabrafenibplaceboadjuvantLow risk of bias -
COMBI-V (Robert), 2015      NCTtrametinib and dabrafenibvemurafenib1L -
vemurafenib and cobimetinib
Larkin, 2014      NCTvemurafenib and cobimetinibvemurafenib -

immune checkpoint inhibition

ipilimumab
Robert, 2011      NCTipilimumab + dacarbazinedacarbazine1L 1st line Low risk of bias -
Hodi (ipi + gp100), 2010      NCTipi + gp100gp1002L 2nd line Risk of bias -
Hodi (ipi alone), 2010      NCTipilimumab 3 mg/kggp1002L 2nd line Risk of bias -
EORTC 18071 (Eggermont), 2015        NCTipilimumabplaceboadjuvant adjuvant Low risk of bias -
nivolumab
CheckMate 037 (Weber), 2015      NCTnivolumabchemotherapy2L, anti-CTLA-4 failure 2nd line Risk of bias -
CheckMate 066 (Robert), 2015      NCTnivolumabdacarbazine1L 1st line Low risk of bias -
CheckMate 238, 2017      NCTnivolumabipilimumabadjuvant adjuvant Low risk of bias -
CheckMate 067 (nivo vs ipi), 2015      NCTnivolumabipilimumab1L 1st line Low risk of bias -
CheckMate 067 (nivo + ipi vs ipi), 2015    NCTnivolumab + ipilimumabipilimumab1L 1st line Low risk of bias -
Postow, 2015      NCTnivolumab + ipilimumabipilimumab1L 1st line Exploratory -
CheckMate 067 (nivo + ipi vs nivo), 2015      NCTnivolumab + ipilimumabnivolumab1L 1st line Exploratory -
pembrolizumab
KEYNOTE 002 (10mg/kg Q3W), 2015      NCTpembrolizumab 10mg/kgchemotherapy2L 2nd line Exploratory -
KEYNOTE 002 (2mg/kg Q3W), 2015      NCTpembrolizumab 2mg/kgchemotherapy2L 2nd line Exploratory -
KEYNOTE-006 (every 2W), 2015      NCTpembrolizumab (every 2W)ipilimumab1L 1st line Risk of bias -
KEYNOTE-006 (every 3W), 2015      NCTpembrolizumab (every 3W)ipilimumab1L 1st line Risk of bias -
KEYNOTE-001, 2014      NCTpembrolizumab 2mg/kgpembrolizumab 10mg/kg2L 2nd line Exploratory -
KEYNOTE-054, 2018      NCTpembrolizumabplaceboadjuvant adjuvant Low risk of bias -

MEK inhibitor

encorafenib plus binimetinib
COLUMBUS, 2018      NCTencorafenib plus binimetinibvemurafenib1LRisk of bias -
selumetinib
Kirkwood, 2012     selumetinibtemozolomide -
Kirkwood   selumetinibtemozolomide -
trametinib + dabrafenib
Flaherty, 2012      NCTtrametinib and dabrafenibdabrafenib -
COMBI-D (Long), 2014        NCTtrametinib and dabrafenibdabrafenib1L unresectable -
COMBI-AD, 2017      NCTtrametinib and dabrafenibplaceboadjuvantLow risk of bias -
COMBI-V (Robert), 2015      NCTtrametinib and dabrafenibvemurafenib1L -
vemurafenib and cobimetinib
Larkin, 2014      NCTvemurafenib and cobimetinibvemurafenib -